{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:40:48Z","timestamp":1790728848320,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["AG 058738"],"award-info":[{"award-number":["AG 058738"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AG041851"],"award-info":[{"award-number":["R01 AG041851"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AG006786"],"award-info":[{"award-number":["U01 AG006786"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 AG062677"],"award-info":[{"award-number":["P30 AG062677"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R37 AG011378"],"award-info":[{"award-number":["R37 AG011378"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 NS097495"],"award-info":[{"award-number":["R01 NS097495"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015595","name":"GHR Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008942","name":"Schuler-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008942","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007048","name":"Mayo Foundation for Medical Education and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.tjpad.2025.100088","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T16:22:21Z","timestamp":1739809341000},"page":"100088","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Eligibility for donanemab trial in a population-based study of cognitive aging"],"prefix":"10.1016","volume":"12","author":[{"given":"Katherine E.","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremiah A.","family":"Aakre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2037-7646","authenticated-orcid":false,"given":"Anna M.","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6591-8734","authenticated-orcid":false,"given":"Vijay K.","family":"Ramanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter K.","family":"Kremers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford R.","family":"Jack Jr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashanthi","family":"Vemuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1466-8357","authenticated-orcid":false,"given":"Christopher G","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5612-1667","authenticated-orcid":false,"given":"Val J.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Knopman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald C.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Graff-Radford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Vassilaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjpad.2025.100088_bib0001","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/alz.13016","article-title":"2023 Alzheimer's disease facts and figures","volume":"19","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100088_bib0002","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/S0140-6736(17)31363-6","article-title":"Dementia prevention, intervention, and care","volume":"390","author":"Livingston","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.tjpad.2025.100088_bib0003","doi-asserted-by":"crossref","first-page":"e1837","DOI":"10.1212\/WNL.0000000000207770","article-title":"Eligibility for anti-amyloid treatment in a population-based study of cognitive aging","volume":"101","author":"Pittock","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.tjpad.2025.100088_bib0004","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/jama.2021.15286","article-title":"Representativeness of participants eligible to Be enrolled in clinical trials of Aducanumab for Alzheimer disease compared with Medicare beneficiaries with Alzheimer Disease and mild cognitive impairment","volume":"326","author":"Anderson","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.tjpad.2025.100088_bib0005","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209402","article-title":"Proportion of community-dwelling individuals older than 70 years eligible for Lecanemab initiation: the Gothenburg H70 birth cohort study","volume":"102","author":"Dittrich","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.tjpad.2025.100088_bib0006","article-title":"FDA greenlights second alzheimer drug, Donanemab","author":"Harris","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.tjpad.2025.100088_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","article-title":"National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease","volume":"8","author":"Hyman","year":"2012","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100088_bib0008","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1016\/j.cell.2023.09.023","article-title":"Accelerating Alzheimer's therapeutic development: the past and future of clinical trials","volume":"186","author":"Boxer","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.tjpad.2025.100088_bib0009","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100088_bib0010","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.tjpad.2025.100088_bib0011","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000115751","article-title":"The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics","volume":"30","author":"Roberts","year":"2008","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.tjpad.2025.100088_bib0012","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.mayocp.2011.11.009","article-title":"Generalizability of epidemiological findings and public health decisions: an illustration from the Rochester Epidemiology Project","volume":"87","author":"St Sauver","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.tjpad.2025.100088_bib0013","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","article-title":"The Clinical Dementia Rating (CDR): current version and scoring rules","volume":"43","author":"Morris","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.tjpad.2025.100088_bib0014","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1001\/archneur.60.12.1777","article-title":"Comparison of the short test of mental status and the mini-mental state examination in mild cognitive impairment","volume":"60","author":"Tang-Wai","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1016\/j.tjpad.2025.100088_bib0015","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","article-title":"Mild cognitive impairment as a diagnostic entity","volume":"256","author":"Petersen","year":"2004","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.tjpad.2025.100088_bib0016","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of alzheimer's disease: report of the NINCDS-ADRDA work group\u22c6 under the auspices of department of health and human services task force on alzheimer's disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/j.tjpad.2025.100088_bib0017","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100088_bib0018","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. ed 4. ed. Washington, DC: American Psychiatric Association; 1994."},{"key":"10.1016\/j.tjpad.2025.100088_bib0019","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","article-title":"Defining imaging biomarker cut points for brain aging and Alzheimer's disease","volume":"13","author":"Jack","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100088_bib0020","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1093\/brain\/awy059","article-title":"Longitudinal tau PET in ageing and Alzheimer's disease","volume":"141","author":"Jack","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.tjpad.2025.100088_bib0021","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcab106","article-title":"Diffusion models reveal white matter microstructural changes with ageing, pathology and cognition","volume":"3","author":"Raghavan","year":"2021","journal-title":"Brain Commun"},{"key":"10.1016\/j.tjpad.2025.100088_bib0022","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.neuroimage.2010.03.020","article-title":"Trajectories of brain aging in middle-aged and older adults: regional and individual differences","volume":"51","author":"Raz","year":"2010","journal-title":"Neuroimage"},{"key":"10.1016\/j.tjpad.2025.100088_bib0023","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1161\/STROKEAHA.119.025822","article-title":"Cardiometabolic health and longitudinal progression of white matter hyperintensity: the Mayo Clinic Study of Aging","volume":"50","author":"Scharf","year":"2019","journal-title":"Stroke"},{"key":"10.1016\/j.tjpad.2025.100088_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2022.106583","article-title":"Population-based prevalence of infarctions on 3D fluid-attenuated inversion recovery (FLAIR) imaging","volume":"31","author":"Cogswell","year":"2022","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.tjpad.2025.100088_bib0025","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S1474-4422(09)70013-4","article-title":"Cerebral microbleeds: a guide to detection and interpretation","volume":"8","author":"Greenberg","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.tjpad.2025.100088_bib0026","doi-asserted-by":"crossref","first-page":"e253","DOI":"10.1212\/WNL.0000000000006780","article-title":"Cerebral microbleeds: prevalence and relationship to amyloid burden","volume":"92","author":"Graff-Radford","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.tjpad.2025.100088_bib0027","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1016\/j.tjpad.2025.100088_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","article-title":"The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET","volume":"11","author":"Klunk","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100088_bib0029","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/brain\/aww023","article-title":"Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages","volume":"139","author":"Schwarz","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.tjpad.2025.100088_bib0030","doi-asserted-by":"crossref","DOI":"10.1002\/gps.5789","article-title":"Potential eligibility for Aducanumab therapy in an Irish specialist cognitive service-utilising cerebrospinal fluid biomarkers and appropriate use criteria","volume":"37","author":"Togher","year":"2022","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.tjpad.2025.100088_bib0031","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/jgs.17530","article-title":"Real-world\" eligibility for aducanumab depends on clinical setting and patients' journey","volume":"70","author":"Padovani","year":"2022","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.tjpad.2025.100088_bib0032","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1111\/jgs.17390","article-title":"Real world\" eligibility for aducanumab","volume":"69","author":"Canevelli","year":"2021","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.tjpad.2025.100088_bib0033","doi-asserted-by":"crossref","first-page":"e674","DOI":"10.1016\/S2666-7568(22)00186-6","article-title":"Comparing clinical trial population representativeness to real-world populations: an external validity analysis encompassing 43 895 trials and 5 685 738 individuals across 989 unique drugs and 286 conditions in England","volume":"3","author":"Tan","year":"2022","journal-title":"Lancet Healthy Longev"},{"key":"10.1016\/j.tjpad.2025.100088_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2023.1256968","article-title":"Patients with geriatric syndromes and anti-amyloid therapies: lack of consideration? An exploratory analysis of the literature","volume":"15","author":"Sadlon","year":"2023","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.tjpad.2025.100088_bib0035","doi-asserted-by":"crossref","first-page":"398","DOI":"10.14283\/jpad.2021.41","article-title":"Aducanumab: appropriate use recommendations","volume":"8","author":"Cummings","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100088_bib0036","doi-asserted-by":"crossref","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: appropriate use recommendations","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100088_bib0037","series-title":"Clinical Trials on Alzheimer's Disease (CTAD) 2024","article-title":"Donanemab: appropriate use recommendations","author":"Rabinovici","year":"2024"},{"key":"10.1016\/j.tjpad.2025.100088_bib0038","doi-asserted-by":"crossref","first-page":"388","DOI":"10.14283\/jpad.2022.50","article-title":"Tackling a major deficiency of diversity in Alzheimer's disease therapeutic trials: an CTAD Task Force report","volume":"9","author":"Raman","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100088_bib0039","unstructured":"US Food and Drug Administration. Full prescribing information, KISUNLA. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761248s000lbl.pdf. Accessed January 20, 2025."},{"key":"10.1016\/j.tjpad.2025.100088_bib0040","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1002\/alz.12782","article-title":"Alzheimer's Association launches ALZ-NET: a long-term data collection and sharing network for new treatments","volume":"18","year":"2022","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100088_bib0041","unstructured":"Alzheimer's Network for Treatment and Diagnostics (ALZ-NET). https:\/\/www.alz-net.org\/. Accessed 27 November 2024."},{"key":"10.1016\/j.tjpad.2025.100088_bib0042","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s40264-019-00848-9","article-title":"Patient registries: an underused resource for Medicines Evaluation: operational proposals for increasing the use of patient registries in regulatory assessments","volume":"42","author":"McGettigan","year":"2019","journal-title":"Drug Saf"},{"key":"10.1016\/j.tjpad.2025.100088_bib0043","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1002\/alz.12959","article-title":"Expectations and clinical meaningfulness of randomized controlled trials","volume":"19","author":"Petersen","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100088_bib0044","doi-asserted-by":"crossref","first-page":"fcad204","DOI":"10.1093\/braincomms\/fcad204","article-title":"Anti-amyloid therapies work for Alzheimer's disease","volume":"5","author":"Hardy","year":"2023","journal-title":"Brain Commun"},{"key":"10.1016\/j.tjpad.2025.100088_bib0045","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/jamaneurol.2018.0629","article-title":"Prevalence and outcomes of amyloid positivity among persons without dementia in a longitudinal, population-based setting","volume":"75","author":"Roberts","year":"2018","journal-title":"JAMA Neurol"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725000329?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725000329?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T21:01:55Z","timestamp":1786482115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580725000329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2274580725000329"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100088","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eligibility for donanemab trial in a population-based study of cognitive aging","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100088","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Mayo Foundation for Medical Education and Research.  Note: https:\/\/www.mayoclinic.org\/copyright\/. Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100088"}}